Patents by Inventor Karina Zuck

Karina Zuck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
    Patent number: 9446021
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 20, 2016
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof
    Publication number: 20150313873
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Application
    Filed: July 9, 2015
    Publication date: November 5, 2015
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W.H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
    Patent number: 9120754
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: September 1, 2015
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof
    Publication number: 20120129837
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Application
    Filed: January 30, 2012
    Publication date: May 24, 2012
    Inventors: Wieslaw M. Cholody, Yi Zang, Norman E. Ohler, Sheela Chellappan, Janak Padia, Karina Zuck, Jeffrey W.H. Watthey, Zoe Ohler, Jeffrey Strovel
  • Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
    Patent number: 8129519
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: March 6, 2012
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Norman E. Ohler, Sheela Chellappan, Janak Padia